FW-04-806 inhibits proliferation and induces apoptosis in human breast cancer cells by binding to N-terminus of Hsp90 and disrupting Hsp90-Cdc37 complex formation

Molecular Cancer

Volumn 13, Issue 1, 2014, Pages

  Huang, Wei ^a,b   Ye, Min ^a,c   Zhang, Lian ru ^d   Wu, Qun dan ^a   Zhang, Min ^a   Xu, Jian hua ^a,c   Zheng, Wei ^a,b  

^a FUJIAN MEDICAL UNIVERSITY   (China)

^b FUJIAN INSTITUTE OF MICROBIOLOGY   (China)

^c Fuijan Provincial Key Laboratory of Natural Medicine Pharmacology   (China)

^d XIAMEN UNIVERSITY   (China)

Author keywords

Breast cancer; Cdc37; FW 04 806; HER2; Hsp90

Indexed keywords

ADENOSINE TRIPHOSPHATASE; ANTINEOPLASTIC AGENT; CASPASE 9; CELL CYCLE PROTEIN 37; CHAPERONE; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; FW 04 806; HEAT SHOCK PROTEIN 90; HEAT SHOCK PROTEIN 90 INHIBITOR; PROTEIN KINASE B; RAF PROTEIN; SMALL INTERFERING RNA; UNCLASSIFIED DRUG; CDC37 PROTEIN, HUMAN; CELL CYCLE PROTEIN; CHAPERONIN; CONGLOBATIN; ERBB2 PROTEIN, HUMAN; MACROLIDE; MULTIPROTEIN COMPLEX; OXAZOLE DERIVATIVE; PROTEIN BINDING;

AMINO TERMINAL SEQUENCE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; BINDING SITE; BREAST CANCER; CELL DEATH; CELL LYSATE; CELL PROLIFERATION; COLORIMETRY; COMPLEX FORMATION; CONTROLLED STUDY; DOWN REGULATION; G2 PHASE CELL CYCLE CHECKPOINT; GENE SILENCING; HUMAN; HUMAN CELL; HYDROGEN BOND; IMMUNOHISTOCHEMISTRY; IMMUNOPRECIPITATION; MCF 7 CELL LINE; MOUSE; NONHUMAN; PROTEIN DEGRADATION; PROTEIN PROTEIN INTERACTION; REAL TIME POLYMERASE CHAIN REACTION; TUMOR XENOGRAFT; ANTAGONISTS AND INHIBITORS; BREAST NEOPLASMS; DRUG EFFECTS; FEMALE; GENETICS; PATHOLOGY; TUMOR CELL LINE;

STREPTOMYCES;

APOPTOSIS; BREAST NEOPLASMS; CELL CYCLE PROTEINS; CELL LINE, TUMOR; CELL PROLIFERATION; CHAPERONINS; FEMALE; HSP90 HEAT-SHOCK PROTEINS; HUMANS; MACROLIDES; MCF-7 CELLS; MULTIPROTEIN COMPLEXES; OXAZOLES; PROTEIN BINDING; RECEPTOR, ERBB-2;

EID: 84902044721     PISSN: None     EISSN: 14764598     Source Type: Journal    
DOI: 10.1186/1476-4598-13-150     Document Type: Article

References (39)

1. Young JC, Agashe VR, Siegers K, Hartl FU. Pathways of chaperone-mediated protein folding in the cytosol. Nat Rev Mol Cell Biol 2004, 5:781-791. 10.1038/nrm1492, 15459659.
2. Welch WJ. Heat shock proteins functioning as molecular chaperones: their roles in normal and stressed cells. Phil Trans Roy Soc Lond B Biol Sci 1993, 339:327-333.
3. Hartl FU. Molecular chaperones in cellular protein folding. Nature 1996, 381:571-579. 10.1038/381571a0, 8637592.
4. Patel HJ, Modi S, Chiosis G, Taldone T. Advances in the discovery and development of heat-shock protein 90 inhibitors for cancer treatment. Expet Opin Drug Discov 2011, 6:559-587.
5. Kamal A, Thao L, Sensintaffar J, Zhang L, Boehm MF, Fritz LC, Burrows FJ. A high-affinity conformation of Hsp90 confers tumour selectivity on Hsp90 inhibitors. Nature 2003, 425:407-410. 10.1038/nature01913, 14508491.
6. Kamal A, Boehm MF, Burrows FJ. Therapeutic and diagnostic implications of Hsp90 activation. Trends Mol Med 2004, 10:283-290. 10.1016/j.molmed.2004.04.006, 15177193.
7. Falsone SF, Gesslbauer B, Tirk F, Piccinini AM, Kungl AJ. A proteomic snapshot of the human heat shock protein 90 interactome. FEBS Lett 2005, 579:6350-6354. 10.1016/j.febslet.2005.10.020, 16263121.
8. Zhao R, Davey M, Hsu YC, Kaplanek P, Tong A, Parsons AB, Krogan N, Cagney G, Mai D, Greenblatt J, Boone C, Emili A, Houry WA. Navigating the chaperone network: an integrative map of physical and genetic interactions mediated by the hsp90 chaperone. Cell 2005, 120:715-727. 10.1016/j.cell.2004.12.024, 15766533.
9. Solit DB, Chiosis G. Development and application of Hsp90 inhibitors. Drug Discov Today 2008, 13:38-43. 10.1016/j.drudis.2007.10.007, 18190862.
10. Taipale M, Jarosz DF, Lindquist S. HSP90 at the hub of protein homeostasis: emerging mechanistic insights. Nat Rev Mol Cell Biol 2010, 11:515-528. 10.1038/nrm2918, 20531426.
11. Mayer MP. Gymnastics of molecular chaperones. Mol Cell 2010, 39:321-331. 10.1016/j.molcel.2010.07.012, 20705236.
12. Hughes PF, Barrott JJ, Carlson DA, Loiselle DR, Speer BL, Bodoor K, Rund LA, Haystead TA. A highly selective Hsp90 affinity chromatography resin with a cleavable linker. Bioorg Med Chem 2012, 20:3298-3305. 10.1016/j.bmc.2012.03.043, 3345094, 22520629.
13. Fadden P, Huang KH, Veal JM, Steed PM, Barabasz AF, Foley B, Hu M, Partridge JM, Rice J, Scott A, Dubois LG, Freed TA, Silinski MA, Barta TE, Hughes PF, Ommen A, Ma W, Smith ED, Spangenberg AW, Eaves J, Hanson GJ, Hinkley L, Jenks M, Lewis M, Otto J, Pronk GJ, Verleysen K, Haystead TA, Hall SE. Application of chemoproteomics to drug discovery: identification of a clinical candidate targeting hsp90. Chem Biol 2010, 17:686-694. 10.1016/j.chembiol.2010.04.015, 20659681.
14. Hong C, Wei J, Wei H, Hui-ling F, Hong J, Wei Z. Optimization of fermentation conditions for FW-04-806, a macrolide dilactone compound with two oxazole ring. Chin J Antibiot 2012, 37:45-49.
15. Westley JW, Liu CM, Evans RH, Blount JF. Conglobatin, a novel macrolide dilactone from Streptomyces conglobatus ATCC 31005. J Antibiot 1979, 32:874-877. 10.7164/antibiotics.32.874, 511778.
16. Wei H, Wei J, Hui-ling F, Hong C, Jian-hua X, Hong J, Wei Z. Structure identification and anti-tumor activity research of FW-04-806. Chin J Antibiot 2011, 36:502-508.
17. Jun-jie C, Qiu-ju G, Xiao-meng H, Shi-xin Y, Cheng C, Lian-ru Z. Study on a Screening Model for Inhibitor of Hsp90 ATPase Activity. J Xiamen University (Nat Science) 2010, 49:711-716.
18. Fonovic M, Verhelst SH, Sorum MT, Bogyo M. Proteomics evaluation of chemically cleavable activity-based probes. Mol Cell Proteomics 2007, 6:1761-1770. 10.1074/mcp.M700124-MCP200, 17615255.
19. Li Y, Karagoz GE, Seo YH, Zhang T, Jiang Y, Yu Y, Duarte AM, Schwartz SJ, Boelens R, Carroll K, Rüdiger SG, Sun D. Sulforaphane inhibits pancreatic cancer through disrupting Hsp90-p50(Cdc37) complex and direct interactions with amino acids residues of Hsp90. J Nutr Biochem 2012, 23:1617-1626. 10.1016/j.jnutbio.2011.11.004, 3386376, 22444872.
20. Rowlands MG, Newbatt YM, Prodromou C, Pearl LH, Workman P, Aherne W. High-throughput screening assay for inhibitors of heat-shock protein 90 ATPase activity. Anal Biochem 2004, 327:176-183. 10.1016/j.ab.2003.10.038, 15051534.
21. Chang L, Bertelsen EB, Wisen S, Larsen EM, Zuiderweg ER, Gestwicki JE. High-throughput screen for small molecules that modulate the ATPase activity of the molecular chaperone DnaK. Anal Biochem 2008, 372:167-176. 10.1016/j.ab.2007.08.020, 17904512.
22. Neckers L. Development of small molecule Hsp90 inhibitors: utilizing both forward and reverse chemical genomics for drug identification. Curr Med Chem 2003, 10:733-739. 10.2174/0929867033457818, 12678776.
23. Whitesell L, Mimnaugh EG, De Costa B, Myers CE, Neckers LM. Inhibition of heat shock protein HSP90-pp60v-src heteroprotein complex formation by benzoquinone ansamycins: essential role for stress proteins in oncogenic transformation. Proc Natl Acad Sci U S A 1994, 91:8324-8328. 10.1073/pnas.91.18.8324, 44598, 8078881.
24. Mimnaugh EG, Chavany C, Neckers L. Polyubiquitination and proteasomal degradation of the p185c-erbB-2 receptor protein-tyrosine kinase induced by geldanamycin. J Biol Chem 1996, 271:22796-22801. 10.1074/jbc.271.37.22796, 8798456.
25. Blagg BS, Kerr TD. Hsp90 inhibitors: small molecules that transform the Hsp90 protein folding machinery into a catalyst for protein degradation. Med Res Rev 2006, 26:310-338. 10.1002/med.20052, 16385472.
26. Neckers L. Chaperoning oncogenes: Hsp90 as a target of geldanamycin. Handb Exp Pharmacol 2006, 172:259-277. 10.1007/3-540-29717-0_11, 16610363.
27. Supko JG, Hickman RL, Grever MR, Malspeis L. Preclinical pharmacologic evaluation of geldanamycin as an antitumor agent. Cancer Chemother Pharmacol 1995, 36:305-315. 10.1007/BF00689048, 7628050.
28. Zhang T, Hamza A, Cao X, Wang B, Yu S, Zhan CG, Sun D. A novel Hsp90 inhibitor to disrupt Hsp90/Cdc37 complex against pancreatic cancer cells. Mol Cancer Ther 2008, 7:162-170. 10.1158/1535-7163.MCT-07-0484, 18202019.
29. Gray PJ, Stevenson MA, Calderwood SK. Targeting Cdc37 inhibits multiple signaling pathways and induces growth arrest in prostate cancer cells. Cancer Res 2007, 67:11942-11950. 10.1158/0008-5472.CAN-07-3162, 18089825.
30. Gray PJ, Prince T, Cheng J, Stevenson MA, Calderwood SK. Targeting the oncogene and kinome chaperone CDC37. Nat Rev Cancer 2008, 8:491-495. 10.1038/nrc2420, 2779120, 18511936.
31. Pearl LH. Hsp90 and Cdc37 - a chaperone cancer conspiracy. Curr Opin Genet Dev 2005, 15:55-61. 10.1016/j.gde.2004.12.011, 15661534.
32. Vaughan CK, Gohlke U, Sobott F, Good VM, Ali MM, Prodromou C, Robinson CV, Saibil HR, Pearl LH. Structure of an Hsp90-Cdc37-Cdk4 complex. Mol Cell 2006, 23:697-707. 10.1016/j.molcel.2006.07.016, 16949366.
33. Silverstein AM, Grammatikakis N, Cochran BH, Chinkers M, Pratt WB. p50(cdc37) binds directly to the catalytic domain of Raf as well as to a site on hsp90 that is topologically adjacent to the tetratricopeptide repeat binding site. J Biol Chem 1998, 273:20090-20095. 10.1074/jbc.273.32.20090, 9685350.
34. Taipale M, Krykbaeva I, Koeva M, Kayatekin C, Westover KD, Karras GI, Lindquist S. Quantitative analysis of HSP90-client interactions reveals principles of substrate recognition. Cell 2012, 150:987-1001. 10.1016/j.cell.2012.06.047, 3894786, 22939624.
35. Sreeramulu S, Gande SL, Gobel M, Schwalbe H. Molecular mechanism of inhibition of the human protein complex Hsp90-Cdc37, a kinome chaperone-cochaperone, by triterpene celastrol. Angew Chem Int Ed Engl 2009, 48:5853-5855. 10.1002/anie.200900929, 19585625.
36. Yang H, Chen D, Cui QC, Yuan X, Dou QP. Celastrol, a triterpene extracted from the Chinese " Thunder of God Vine," is a potent proteasome inhibitor and suppresses human prostate cancer growth in nude mice. Cancer Res 2006, 66:4758-4765. 10.1158/0008-5472.CAN-05-4529, 16651429.
37. Yu Y, Hamza A, Zhang T, Gu M, Zou P, Newman B, Li Y, Gunatilaka AA, Zhan CG, Sun D. Withaferin A targets heat shock protein 90 in pancreatic cancer cells. Biochem Pharmacol 2010, 79:542-551. 10.1016/j.bcp.2009.09.017, 2794909, 19769945.
38. Grover A, Agrawal V, Shandilya A, Bisaria VS, Sundar D. Non-nucleosidic inhibition of Herpes simplex virus DNA polymerase: mechanistic insights into the anti-herpetic mode of action of herbal drug withaferin A. BMC Bioinformatics 2011, 12(Suppl 13):S22.
39. Xu W, Mimnaugh E, Rosser MF, Nicchitta C, Marcu M, Yarden Y, Neckers L. Sensitivity of mature Erbb2 to geldanamycin is conferred by its kinase domain and is mediated by the chaperone protein Hsp90. J Biol Chem 2001, 276:3702-3708. 10.1074/jbc.M006864200, 11071886.